Rare diseases

News
Alnylam

Alnylam beats Ionis in RNA drug battle

Alnylam and Sanofi have revealed full phase 3 data on their RNA interference (RNAi) drug patisiran, soundly beating a rival candidate from Ionis, inotersen.